Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study
Metrics: PDF 1473 views | HTML 2659 views | ?
Huaping Chen1,*, Siyuan Chen1,*, Shan Li1,*, Zhijian Chen1, Xuan Zhu1, Meiyu Dai1, Lingxi Kong1, Xiaodan Lv1, Zhili Huang1 and Xue Qin1
1Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
*These authors contributed equally to this work and should be considered as co-first authors
Xue Qin, email: [email protected]
Keywords: des-gamma-carboxyprothrombin, AFP, hepatocellular cancer, diagnosis, meta-analysis
Received: June 22, 2017 Accepted: July 30, 2017 Published: August 07, 2017
Controversies about the combination of des-gamma-carboxyprothrombin (DCP) and alpha-fetoprotein (AFP) for hepatocellular carcinoma diagnosing still exist. Hence, we performed this updated meta-analysis to estimate the diagnostic value of DCP , AFP and DCP + AFP in HCC. In addition, we conducted a validation study to analyze the performance of the candidate makers. After a systematic literature review, 27 studies from 20 articles were identified from four major databases. The pooled sensitivity and specificity were 69% and 89%, respectively, for DCP; for AFP, they were 65% and 88%, respectively; and they were 82% and 85%, respectively, for DCP + AFP. The values of the area under the curve (AUC) for DCP, AFP, DCP + AFP, respectively, were 0.88, 0.75, and 0.90. The validation study confirmed that the performance of DCP + AFP (sensitivity = 84%, specificity = 86%; AUC = 0.887) was higher than that of DCP (sensitivity = 76%, specificity = 92%; AUC = 0.843) or AFP (sensitivity = 73%, specificity = 92%; AUC = 0.837) alone.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.